Product debut follows “stunning results” of GLP-standardized in

vivo study for long-term use of MOBYBOX

  • Key endpoints in all study subjects — no hemolysis, no
    thrombosis and no functional device wear — to be used for CE mark
    registration of MOBYBOX, the initial application of Hemovent’s
    Bionique technology platform

AACHEN, Germany--(BUSINESS WIRE)--Hemovent

GmbH announced today it is debuting its next-gen MOBYBOX system

to clinicians at the 29th Annual ELSO Conference, Sept.

13-16, in Scottsdale, Ariz., USA.

MOBYBOX has recently and successfully completed a GLP-standardized in

vivo study for long-term (7 days) use. MOBYBOX is based on

Hemovent’s novel and portable Bionique artificial lung technology

platform, designed for a wide range of indications: from ExtraCorporeal

Life Support (ECLS) to ExtraCorporeal CO2

Removal (ECCO2R).

“We are extremely pleased to be introducing MOBYBOX at one of the

leading scientific meetings in the world. ELSO is an international

nonprofit consortium of healthcare institutions that are dedicated to

the development and evaluation of novel therapies for support of failing

organ systems,” said Christof Lenz, a co-founder and CEO of

Hemovent. “We expect that the outstanding results from our recent in

vivo study will create quite a buzz at ELSO. When our initial

technology application, MOBYBOX, is commercially available, it

will simplify ECMO usage, not only for life support applications (ECLS)

but also as an effective therapy for respiratory failure indications

including ECCO2R protocols,” added Lenz.

These types of applications — ECLS and ECCO2R — are also known as

ExtraCorporeal Membrane Oxygenation (ECMO): the establishment of an

artificial external blood circuit with a pump and gas exchanger system

in order to support the lung function only or even establish a

full cardiopulmonary bypass.

Hemovent is an emerging medical device company that has developed a

self-contained and easy-to-use artificial lung for ExtraCorporeal

Membrane Oxygenation (ECMO) /ExtraCorporeal Life Support (ECLS)

applications designed to support or replace heart and lung function in

the event of cardiac and/or respiratory failure.

CAUTION: The Hemovent ECMO/ECLS System based on Bionique technology is

not yet approved for human use.


Ronald Trahan Associates

Ronald Trahan, APR, +1-508-816-6730